(Corrects NOV 27 item to "more than 11%", paragraph 5)
* Oil stocks record worst day in nearly a month
* ASX 200 still on track for best month ever
Nov 27 (Reuters) - Australian shares ended lower on Friday
as renewed doubts about a promising coronavirus vaccine dented
investor sentiment, while Treasury Wine dived on China's plans
to impose temporary anti-dumping measures on Australian wine
The S&P/ASX 200 index fell 0.5% to end the session
at 6,601.1 points and close lower for the second straight day.
Global markets eased after several scientists questioned
some efficacy results of a trial of UK drugmaker AstraZeneca's
COVID-19 vaccine candidate, stoking worries that this
could lead to a delay in key approvals.
"It's likely the company will start a new trial to firm up
results. The news was enough to trigger profit taking, given the
importance of a vaccine to market confidence," said Michael
McCarthy, chief market strategist at CMC Markets and
Optimism around multiple potential effective coronavirus
treatments have partly buoyed stock markets in November, with
the Australian bourse on track for its best month ever on the
back of a more than 11% jump.
Treasury Wine Estates Ltd plunged more than 14% and
was the worst performer on the ASX 200 before trading in its
shares was halted.
China said it will impose temporary anti-dumping tariffs on
wine imported from Australia from Nov. 28, with Treasury Wine
required to pay the highest deposit to China's customs authority
of all wine importers.
Oil stocks incurred the most losses as they fell
1.8%, led by Beach Energy Ltd which dropped 3.8% and
Oil Search Ltd which gave up 3.7%.
Technology stocks, financials and miners
In New Zealand, the benchmark S&P/NZX 50 index
closed 0.3% higher.
(Reporting by Shashwat Awasthi in Bengaluru; Editing by Shounak